James F. Maher

528 total citations
8 papers, 420 citations indexed

About

James F. Maher is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, James F. Maher has authored 8 papers receiving a total of 420 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 3 papers in Pathology and Forensic Medicine and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in James F. Maher's work include Lung Cancer Diagnosis and Treatment (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Cancer Treatment and Pharmacology (2 papers). James F. Maher is often cited by papers focused on Lung Cancer Diagnosis and Treatment (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Cancer Treatment and Pharmacology (2 papers). James F. Maher collaborates with scholars based in United States and Canada. James F. Maher's co-authors include Joseph N. Cunningham, G. Tom Shires, H Illner, Thomas E. Roche, Edward L. Middleman, Martin R. Weber, David H. Ellison, Yasmin Alam, Pamela A. Silver and Helen J. Ross and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Annals of Surgery.

In The Last Decade

James F. Maher

8 papers receiving 397 citations

Peers

Countries citing papers authored by James F. Maher

Since Specialization

Citations

This map shows the geographic impact of James F. Maher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James F. Maher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James F. Maher more than expected).

Fields of papers citing papers by James F. Maher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James F. Maher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James F. Maher. The network helps show where James F. Maher may publish in the future.

Co-authorship network of co-authors of James F. Maher

This figure shows the co-authorship network connecting the top 25 collaborators of James F. Maher. A scholar is included among the top collaborators of James F. Maher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James F. Maher. James F. Maher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	Randomized Phase II Adjuvant Trial of Dose-Dense Docetaxel Before or After Doxorubicin Plus Cyclophosphamide in Axillary Node-Positive Breast Cancer 2008 ·Journal of Clinical Oncology ·Shannon Puhalla, Ewa Mrózek, Donn C. Young, (unknown), (unknown), Kari Kendra, (unknown), Mark Knapp, Taral Patel, Mark E. Thompson, James F. Maher, Timothy D. Moore, Charles L. Shapiro	21
2	Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer 2007 ·Journal of Clinical Oncology ·Charles Butts, David Bodkin, Edward L. Middleman, (unknown), David H. Ellison, Yasmin Alam, Harvey Kreisman, Peter R. Graze, James F. Maher, Helen J. Ross, Peter Ellis, William McNulty, Edward J. Kaplan, (unknown), Martin R. Weber, Frances A. Shepherd	160
3	O-098 Survival equivalence of non-platinum-based and platinum-basedchemotherapy for advanced non-small cell lung cancer (NSCLC): The results of a multicenter internet-based Phase III randomized study (D0112) 2005 ·Lung Cancer ·James R. Rigas, (unknown), (unknown), (unknown), (unknown), (unknown), F. Yunus, Mark A. Rubin, Hassan Ghazal, James F. Maher	7
4	Taxanes and Capecitabine in Combination: Rationale and Clinical Results 2002 ·Clinical Breast Cancer ·James F. Maher, Miguel A. Villalona‐Calero	17
5	Colorectal cancer in Russian-speaking Jewish emigres: community-based screening 2001 ·The American Journal of Gastroenterology ·(unknown), James F. Maher, (unknown), (unknown), (unknown), John C. Winkelmann, Stephen Goldberg	7
6	The membrane proteins of the methanol-induced peroxisome of Candida boidinii. Initial characterization and generation of monoclonal antibodies. 1986 ·Journal of Biological Chemistry ·Joel Goodman, James F. Maher, Pamela A. Silver, A. Pacifico, Dale Sanders	48
7	Purification of Bovine Kidney and Heart Pyruvate Dehydrogenaseb Phosphatase on Sepharose Derivatized with the Pyruvate Dehydrogenase Complex 1982 ·European Journal of Biochemistry ·(unknown), James F. Maher, Thomas E. Roche	38
8	Alterations in Cellular Membrane Function During Hemorrhagic Shock in Primates 1972 ·Annals of Surgery ·G. Tom Shires, Joseph N. Cunningham, (unknown), (unknown), H Illner, (unknown), James F. Maher	122

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact